HTL0018318 is a selective muscarinic M receptor partial agonist under development for the symptomatic treatment of dementias, including Alzheimer's disease. Clinically, HTL0018318 would likely be used alone or in conjunction with cholinesterase inhibitors (e.g. donepezil).
Safety and Pharmacokinetics of HTL0018318, a Novel M Receptor Agonist, Given in Combination with Donepezil at Steady State: A Randomized Trial in Healthy Elderly Subjects.
CHDR
Bakker C, van der Aart J, Labots G, Liptrot J, Cross DM, Klaassen ES, Dickinson S, Tasker T, Groeneveld GJ
